Eilon Kirson compensation by year
NovoCure Summary Compensation Table · all 3 fiscal years held| Component | FY2016 | FY2017 | FY2018 |
|---|---|---|---|
| Salary | $419,570 | $455,284 | $461,783 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $0 | $780,780 | $440,618 |
| Option awards | $489,520 | $1,116,133 | $1,769,541 |
| Non-equity incentive | $0 | $286,075 | $286,340 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $128,639 | $204,319 | $184,522 |
| Total | $1,037,729 | $2,842,591 | $3,142,804 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: NovoCure Ltd DEF 14A filed April 10, 2019, accession 0001564590-19-011243, and prior-year filings. Open the filing on EDGAR.
How this page was built: the NovoCure Ltd filed document, accession 0001564590-19-011243. Every figure is read from that document and cited to the page and table it appears in. Filed April 10, 2019.
Equity holdings
unvested awards at FY2018 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 72,799 | $2,437,311 | — |
| PSU | 20,833 | $697,489 | — |
| Option | 152,068 | — | $21.15 |
| Option | 204,750 | — | $7.15 |
| Option | 37,500 | — | $11.46 |
| Option | 66,522 | — | $14.37 |
Per the Outstanding Equity Awards at Fiscal Year-End table in NovoCure Ltd's FY2018 proxy; value at the fiscal year-end close, as the company printed it.
NovoCure’s named executive officers, FY2018
as the company reported each| Named executive officer | Role | FY2018 total |
|---|---|---|
| Asaf Danziger | Chief Executive Officer | $4,570,294 |
| William Doyle | Executive Chairman | $4,558,655 |
| Wilhelmus Groenhuysen | Chief Financial Officer | $3,459,217 |
| Eilon Kirson · this page | Chief Science Officer and Head of R&D | $3,142,804 |
| Pritesh Shah | Chief Commercial Officer | $3,070,496 |
| Michael Ambrogi | Chief Operating Officer | $2,611,707 |
The full NovoCure compensation record
free company briefThis page is one person within NovoCure's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the NovoCure proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are NovoCure's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.